TRICARE Expands Cancer Clinical Trials Demonstration

Publication
Article
OncologyONCOLOGY Vol 13 No 8
Volume 13
Issue 8

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute (NCI). The demonstration had previously been limited to cancer treatment trials. The expansion, effective in June, was somewhat of a last-ditch effort to entice more TRICARE beneficiaries into the demonstration so that TRICARE could obtain more data on which to base future decisions. Between January 1996 and August 1998, only 155 TRICARE beneficiaries enrolled in NCI trials, and those were almost exclusively for bone marrow transplants.

Of course, TRICARE has a much better record on covering patient costs of participating in cancer clinical trials than almost any other health plan. Sens. Jay Rockefeller (D-W. Va.) and Connie Mack (R-Fla.) have been trying for years to persuade Congress to pass a bill authorizing a Medicare demonstration that would ensure coverage of patient care costs. No bill has ever gotten out of a Senate committee.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.